Hela Romdhani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hela Romdhani has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Daisy Liu
Analysis Group, Inc., Boston, USA
3 shared publicationsDonna Rowen
Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK
3 shared publications- Elamin H. Elbasha
Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA
3 shared publications - Jipan Xie
XL Source, Inc., Los Angeles, USA
3 shared publications - Matthew. S. Kelly
University of Arkansas for Medical Sciences
3 shared publications - Min Huang
Merck & Co., Inc., Rahway, USA
3 shared publications
Latest Publications
- Open Access
- 30 May 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1881-1902
Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis
Growing evidence suggests that first-line (1L) treatment with high-efficacy disease-modifying therapies (HE-DMTs) may have greater clinical benefit in multiple sclerosis (MS) than delaying HE-DMTs to second- or subsequent-line (2L+) therapy. However, MS treatment is often initiated using an escalation approach, involving initial treatment with low- to moderate-efficacy DMTs followed by escalation to HE-DMTs in the presence of new disease activity or disability worsening. Ocrelizumab is a HE-DMT approved for the treatment of relapsing and primary progressive MS, but real-world outcomes of ocrelizumab as a 1L vs 2L+ therapy are not well characterized. Real-world data from people with MS (pwMS) receiving treatment at four centers in the USA were analyzed. The effectiveness of ocrelizumab when administered as 1L or 2L+ treatment was compared for up to 60 months in follow-up. The primary outcome was time to confirmed disability worsening (based on Patient-Determined Disease Steps [PDDS]). Secondary outcomes were time to requiring a walking aid (PDDS ≥ 4), annualized patient-reported relapse rate, and magnetic resonance imaging measures (e.g., brain volume and number and volume of new T2 lesions). A total of 403 pwMS (1L n = 309, 2L+ n = 94) were identified. Overall, pwMS who received 1L ocrelizumab experienced less confirmed disease worsening (25.8% vs 42.6%; P = 0.03) and requirement for a walking aid (6.5% vs 27.4%; P < 0.01) compared with the 2L+ cohort. The 1L group also had a significantly lower change in T2 lesion volume (mean difference - 0.797 mL; P < 0.05) and a lower risk of developing new T2 lesions than the 2L+ group (incidence rate ratio 0.88 [95% CI 0.78-0.99]; P = 0.04). Relapse rate and brain volume outcomes were not significantly different between groups. This study contributes to the growing pool of evidence that 1L treatment with HE-DMTs such as ocrelizumab can improve clinical outcomes for pwMS compared with delaying HE-DMT to 2L+ .
- 30 May 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1881-1902
Open AccessEarly Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis
Growing evidence suggests that first-line (1L) treatment with high-efficacy disease-modifying therapies (HE-DMTs) may have greater clinical benefit in multiple sclerosis (MS) than delaying HE-DMTs to second- or subsequent-line (2L+) therapy. However, MS treatment is often initiated using an escalation approach, involving initial treatment with low- to moderate-efficacy DMTs followed by escalation to HE-DMTs in the presence of new disease activity or disability worsening. Ocrelizumab is a HE-DMT approved for the treatment of relapsing and primary progressive MS, but real-world outcomes of ocrelizumab as a 1L vs 2L+ therapy are not well characterized. Real-world data from people with MS (pwMS) receiving treatment at four centers in the USA were analyzed. The effectiveness of ocrelizumab when administered as 1L or 2L+ treatment was compared for up to 60 months in follow-up. The primary outcome was time to confirmed disability worsening (based on Patient-Determined Disease Steps [PDDS]). Secondary outcomes were time to requiring a walking aid (PDDS ≥ 4), annualized patient-reported relapse rate, and magnetic resonance imaging measures (e.g., brain volume and number and volume of new T2 lesions). A total of 403 pwMS (1L n = 309, 2L+ n = 94) were identified. Overall, pwMS who received 1L ocrelizumab experienced less confirmed disease worsening (25.8% vs 42.6%; P = 0.03) and requirement for a walking aid (6.5% vs 27.4%; P < 0.01) compared with the 2L+ cohort. The 1L group also had a significantly lower change in T2 lesion volume (mean difference - 0.797 mL; P < 0.05) and a lower risk of developing new T2 lesions than the 2L+ group (incidence rate ratio 0.88 [95% CI 0.78-0.99]; P = 0.04). Relapse rate and brain volume outcomes were not significantly different between groups. This study contributes to the growing pool of evidence that 1L treatment with HE-DMTs such as ocrelizumab can improve clinical outcomes for pwMS compared with delaying HE-DMT to 2L+ .
- Open Access
- 1 April 2026
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (3) , 407-422
Health Utilities Associated with Pneumococcal Diseases in Children and Adults: A Targeted Literature Review and Meta-analysis
Background Pneumococcal disease and post-meningitis sequelae (PMS) impact health-related quality of life (HRQoL). However, health utility estimates for these conditions vary considerably in the literature, which may affect the outcomes of economic evaluations. Objectives The aim was to generate pooled estimates of quality-adjusted life year (QALY) decrements per episode for pneumococcal disease and pooled health state utility value (HSUV) estimates for PMS in children and adults. Methods Global targeted literature reviews were conducted in MEDLINE in June 2024 to identify original studies on the health utilities of pneumococcal disease and PMS. Random-effects meta-analyses were conducted separately for children (< 18 years) and adults (≥ 18 years) to calculate pooled estimates of QALY decrements per episode for pneumococcal disease states and pooled HSUV estimates for PMS. Results A total of 40 studies, published from 1993–2022, were included. Fifteen were conducted among children, 19 among adults, and six among both age groups. In children, the pooled QALY decrement estimates (95% confidence interval [CI]) per episode were 0.023 (0.017–0.030) for meningitis, 0.010 (0.003–0.017) for bacteremia/sepsis, 0.014 (0.002–0.026) for inpatient pneumonia, 0.010 (0.002–0.017) for outpatient pneumonia, 0.008 (0.003–0.013) for unspecified pneumonia, 0.005 (0.005–0.006) for recurrent/complex acute otitis media (AOM), and 0.003 (0.001–0.005) for simple AOM. The pooled HSUV estimates for PMS in children were 0.485 (0.322–0.649) for neurological deficits, 0.701 (0.563–0.839) for hearing loss, and 0.827 (0.713–0.941) for unspecified PMS. In adults, the pooled QALY decrement estimates per episode (95% CI) were 0.027 (0.018–0.036) for meningitis, 0.013 (0.000–0.027) for bacteremia/sepsis, 0.015 (0.008–0.021) for inpatient pneumonia, 0.007 (0.005–0.008) for outpatient pneumonia, and 0.009 (0.001–0.018) for unspecified pneumonia. The pooled HSUV estimates for PMS in adults were 0.556 (0.447–0.665) for neurological deficits, 0.700 (0.631–0.768) for hearing loss, and 0.778 (0.744–0.812) for unspecified PMS. Moderate to high heterogeneity levels were observed in most of the meta-analyses performed in this study. Conclusions Pneumococcal disease and PMS substantially reduce HRQoL in children and adults, with the greatest impacts observed with meningitis, inpatient pneumonia, and bacteremia/sepsis. There is considerable variability in utility estimates across studies, likely driven by methodological differences. This analysis provides a comprehensive quantitative synthesis of QALY decrement estimates for pneumococcal disease states and HSUV estimates for PMS, improving our understanding of the HRQoL burden and potentially enhancing the comparability of future economic evaluations of pneumococcal vaccines.
- 1 April 2026
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (3) , 407-422
Open AccessHealth Utilities Associated with Pneumococcal Diseases in Children and Adults: A Targeted Literature Review and Meta-analysis
Background Pneumococcal disease and post-meningitis sequelae (PMS) impact health-related quality of life (HRQoL). However, health utility estimates for these conditions vary considerably in the literature, which may affect the outcomes of economic evaluations. Objectives The aim was to generate pooled estimates of quality-adjusted life year (QALY) decrements per episode for pneumococcal disease and pooled health state utility value (HSUV) estimates for PMS in children and adults. Methods Global targeted literature reviews were conducted in MEDLINE in June 2024 to identify original studies on the health utilities of pneumococcal disease and PMS. Random-effects meta-analyses were conducted separately for children (< 18 years) and adults (≥ 18 years) to calculate pooled estimates of QALY decrements per episode for pneumococcal disease states and pooled HSUV estimates for PMS. Results A total of 40 studies, published from 1993–2022, were included. Fifteen were conducted among children, 19 among adults, and six among both age groups. In children, the pooled QALY decrement estimates (95% confidence interval [CI]) per episode were 0.023 (0.017–0.030) for meningitis, 0.010 (0.003–0.017) for bacteremia/sepsis, 0.014 (0.002–0.026) for inpatient pneumonia, 0.010 (0.002–0.017) for outpatient pneumonia, 0.008 (0.003–0.013) for unspecified pneumonia, 0.005 (0.005–0.006) for recurrent/complex acute otitis media (AOM), and 0.003 (0.001–0.005) for simple AOM. The pooled HSUV estimates for PMS in children were 0.485 (0.322–0.649) for neurological deficits, 0.701 (0.563–0.839) for hearing loss, and 0.827 (0.713–0.941) for unspecified PMS. In adults, the pooled QALY decrement estimates per episode (95% CI) were 0.027 (0.018–0.036) for meningitis, 0.013 (0.000–0.027) for bacteremia/sepsis, 0.015 (0.008–0.021) for inpatient pneumonia, 0.007 (0.005–0.008) for outpatient pneumonia, and 0.009 (0.001–0.018) for unspecified pneumonia. The pooled HSUV estimates for PMS in adults were 0.556 (0.447–0.665) for neurological deficits, 0.700 (0.631–0.768) for hearing loss, and 0.778 (0.744–0.812) for unspecified PMS. Moderate to high heterogeneity levels were observed in most of the meta-analyses performed in this study. Conclusions Pneumococcal disease and PMS substantially reduce HRQoL in children and adults, with the greatest impacts observed with meningitis, inpatient pneumonia, and bacteremia/sepsis. There is considerable variability in utility estimates across studies, likely driven by methodological differences. This analysis provides a comprehensive quantitative synthesis of QALY decrement estimates for pneumococcal disease states and HSUV estimates for PMS, improving our understanding of the HRQoL burden and potentially enhancing the comparability of future economic evaluations of pneumococcal vaccines.
- Open Access
- 10 December 2025
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (1) , 5-33
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews
Background Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost-utility analyses (CUAs) to evaluate the economic value of pneumococcal vaccines. Objectives This study aimed to synthesize utility values used in CUAs of pneumococcal vaccines in adult populations in North America and Europe and to summarize global utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in adults. Methods Two targeted literature reviews were conducted in June 2024 using MEDLINE to identify CUAs of pneumococcal vaccines and original studies on health utilities for pneumococcal disease and PMS in adults. References from existing literature reviews on QoL associated with pneumococcal disease and CUAs of pneumococcal vaccines were also screened to identify additional original utility studies. Health utility input values applied in the CUAs were summarized, and the original source studies were reviewed. Utility and disutility inputs were converted to QALY decrements using disease durations reported in the CUAs. Methods and utility estimates from original utility studies were summarized for each health state. Results Sixty-five CUAs focusing on adults in North America and Europe were identified. These CUAs frequently reported utility values and QALY decrements. The ranges of reported and derived QALY decrements were 0.006–0.8 for unspecified invasive pneumococcal disease (IPD), 0.0013–0.1759 for meningitis, 0.0010–0.1759 for non-meningitis IPD, 0.0002–0.13 for inpatient pneumonia, and 0.0001–0.0115 for outpatient pneumonia. The ranges of reported utility values for PMS were 0.319–0.83 for neurological deficits and 0.635–0.91 for hearing loss. Twenty-five original utility studies in adults were identified, published between 1993 and 2022. Utility estimates from these studies showed considerable variability, with ranges of − 0.330 to 0.39 for meningitis, − 0.331 to 0.93 for non-meningitis IPD, − 0.054 to 0.71 for inpatient pneumonia, 0.35–0.825 for outpatient pneumonia, 0.217–0.89 for neurological deficits, and 0.433–0.89 for hearing loss. This variability was primarily attributable to differences in case definitions, preference weights, and geographical locations. Conclusions This review identified substantial QoL burden associated with pneumococcal disease and PMS in adults; however, considerable variability in utility estimates exists. Utility inputs in CUAs of pneumococcal vaccines in adults often rely upon assumptions, pediatric studies, or utilities from other diseases, and there is relatively little data on the health utilities of IPD and neurological deficits in adults. Given the importance of health utilities in economic evaluations, CUAs should carefully select utility values by considering methodological robustness, the representativeness of health states, and the time frame over which health utilities are assessed and evaluate alternative sources and assumptions in sensitivity analyses.
- 10 December 2025
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (1) , 5-33
Open AccessGlobal Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews
Background Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost-utility analyses (CUAs) to evaluate the economic value of pneumococcal vaccines. Objectives This study aimed to synthesize utility values used in CUAs of pneumococcal vaccines in adult populations in North America and Europe and to summarize global utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in adults. Methods Two targeted literature reviews were conducted in June 2024 using MEDLINE to identify CUAs of pneumococcal vaccines and original studies on health utilities for pneumococcal disease and PMS in adults. References from existing literature reviews on QoL associated with pneumococcal disease and CUAs of pneumococcal vaccines were also screened to identify additional original utility studies. Health utility input values applied in the CUAs were summarized, and the original source studies were reviewed. Utility and disutility inputs were converted to QALY decrements using disease durations reported in the CUAs. Methods and utility estimates from original utility studies were summarized for each health state. Results Sixty-five CUAs focusing on adults in North America and Europe were identified. These CUAs frequently reported utility values and QALY decrements. The ranges of reported and derived QALY decrements were 0.006–0.8 for unspecified invasive pneumococcal disease (IPD), 0.0013–0.1759 for meningitis, 0.0010–0.1759 for non-meningitis IPD, 0.0002–0.13 for inpatient pneumonia, and 0.0001–0.0115 for outpatient pneumonia. The ranges of reported utility values for PMS were 0.319–0.83 for neurological deficits and 0.635–0.91 for hearing loss. Twenty-five original utility studies in adults were identified, published between 1993 and 2022. Utility estimates from these studies showed considerable variability, with ranges of − 0.330 to 0.39 for meningitis, − 0.331 to 0.93 for non-meningitis IPD, − 0.054 to 0.71 for inpatient pneumonia, 0.35–0.825 for outpatient pneumonia, 0.217–0.89 for neurological deficits, and 0.433–0.89 for hearing loss. This variability was primarily attributable to differences in case definitions, preference weights, and geographical locations. Conclusions This review identified substantial QoL burden associated with pneumococcal disease and PMS in adults; however, considerable variability in utility estimates exists. Utility inputs in CUAs of pneumococcal vaccines in adults often rely upon assumptions, pediatric studies, or utilities from other diseases, and there is relatively little data on the health utilities of IPD and neurological deficits in adults. Given the importance of health utilities in economic evaluations, CUAs should carefully select utility values by considering methodological robustness, the representativeness of health states, and the time frame over which health utilities are assessed and evaluate alternative sources and assumptions in sensitivity analyses.
- 23 May 2025
- Published by Springer Nature in PharmacoEconomics
- Vol. 43 (9) , 1001-1045
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews
Background Pneumococcal disease can significantly impact the quality of life (QoL) of children. Health utilities are used to measure the disease burden and calculate quality-adjusted life year (QALY) estimates. These estimates provide critical inputs in economic evaluations of pneumococcal vaccines in children. Objectives This study aimed to synthesize utility values used in cost-utility analyses (CUAs) of pediatric pneumococcal vaccines and to summarize published utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in children on a global scale. Methods Two targeted literature reviews were conducted to identify CUAs of pediatric pneumococcal vaccines and original studies on health utilities of pneumococcal disease and PMS. Both literature reviews identified relevant studies using published reviews, supplemented by de novo searches conducted in MEDLINE in June 2024 to cover periods not included in those reviews. References from published literature reviews on QoL of pneumococcal disease and CUAs were screened to identify additional original utility studies. Health utility values applied in the CUAs were summarized and the source studies for these utilities were reviewed. For original utility studies, methods and utility estimates were summarized for each condition. Results The study identified 45 CUAs of pediatric pneumococcal vaccines in North America and Europe published from 2004 to 2024, and 21 original utility studies on pneumococcal disease or PMS in children published globally from 1994 to 2017. QALY decrement was the most common utility input in CUAs. Most CUAs referenced an earlier CUA for utility inputs, which were often sourced from one or two original utility studies for each health state. Most source studies were published more than two decades ago; some common source studies were conducted in adults. Utility estimates from original studies showed considerable variability, with ranges of −0.330 to 0.6882 for meningitis, −0.331 to 0.93 for non-meningitis invasive pneumococcal disease (IPD), −0.054 to 0.71 for inpatient pneumonia, 0.412–0.82 for outpatient pneumonia, 0.389–0.97 for acute otitis media (AOM)/simple AOM, 0.434–0.540 for recurrent AOM, −0.33 to 0.89 for neurological deficits, and 0.217–0.97 for hearing loss. Variability in methods, including in the surveyed population, utility elicitation method, and use of different country-specific preference weights, substantially impacted utility values. Overall, the methods were not suitable for temporary health states. Additionally, many studies used instruments that have not been validated in children. Conclusions Original utility studies demonstrated that pneumococcal disease and PMS are associated with impaired QoL in children; however, there was considerable variability in utility estimates across studies, reflecting the inherent methodological challenges in estimating utilities for acute diseases in children. Most CUAs referenced previous CUAs for health utility values, which were sourced from a limited number of outdated original utility studies. Contemporary data and methods adapted for acute diseases in children are needed for future studies. Given the significance of health utilities in the economic valuations of new pneumococcal vaccines, utility values should be carefully selected in CUAs, considering alternative sources and assumptions.
- 23 May 2025
- Published by Springer Nature in PharmacoEconomics
- Vol. 43 (9) , 1001-1045
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews
Background Pneumococcal disease can significantly impact the quality of life (QoL) of children. Health utilities are used to measure the disease burden and calculate quality-adjusted life year (QALY) estimates. These estimates provide critical inputs in economic evaluations of pneumococcal vaccines in children. Objectives This study aimed to synthesize utility values used in cost-utility analyses (CUAs) of pediatric pneumococcal vaccines and to summarize published utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in children on a global scale. Methods Two targeted literature reviews were conducted to identify CUAs of pediatric pneumococcal vaccines and original studies on health utilities of pneumococcal disease and PMS. Both literature reviews identified relevant studies using published reviews, supplemented by de novo searches conducted in MEDLINE in June 2024 to cover periods not included in those reviews. References from published literature reviews on QoL of pneumococcal disease and CUAs were screened to identify additional original utility studies. Health utility values applied in the CUAs were summarized and the source studies for these utilities were reviewed. For original utility studies, methods and utility estimates were summarized for each condition. Results The study identified 45 CUAs of pediatric pneumococcal vaccines in North America and Europe published from 2004 to 2024, and 21 original utility studies on pneumococcal disease or PMS in children published globally from 1994 to 2017. QALY decrement was the most common utility input in CUAs. Most CUAs referenced an earlier CUA for utility inputs, which were often sourced from one or two original utility studies for each health state. Most source studies were published more than two decades ago; some common source studies were conducted in adults. Utility estimates from original studies showed considerable variability, with ranges of −0.330 to 0.6882 for meningitis, −0.331 to 0.93 for non-meningitis invasive pneumococcal disease (IPD), −0.054 to 0.71 for inpatient pneumonia, 0.412–0.82 for outpatient pneumonia, 0.389–0.97 for acute otitis media (AOM)/simple AOM, 0.434–0.540 for recurrent AOM, −0.33 to 0.89 for neurological deficits, and 0.217–0.97 for hearing loss. Variability in methods, including in the surveyed population, utility elicitation method, and use of different country-specific preference weights, substantially impacted utility values. Overall, the methods were not suitable for temporary health states. Additionally, many studies used instruments that have not been validated in children. Conclusions Original utility studies demonstrated that pneumococcal disease and PMS are associated with impaired QoL in children; however, there was considerable variability in utility estimates across studies, reflecting the inherent methodological challenges in estimating utilities for acute diseases in children. Most CUAs referenced previous CUAs for health utility values, which were sourced from a limited number of outdated original utility studies. Contemporary data and methods adapted for acute diseases in children are needed for future studies. Given the significance of health utilities in the economic valuations of new pneumococcal vaccines, utility values should be carefully selected in CUAs, considering alternative sources and assumptions.
- Open Access
- 21 May 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 743-752
Non-optimal treatment with first tyrosine kinase inhibitor and associated economic burden in chronic myeloid leukemia
Although adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKI) approved by the Food and Drug Administration have demonstrated effectiveness in treating chronic myeloid leukemia (CML), patients often experience intolerance or resistance, leading to non-optimal treatment (NOPT). This study assessed the treatment patterns, as well as NOPT and its associated economic burden, in newly diagnosed patients with CML receiving first TKI treatment. This retrospective study identified adult patients with ≥2 CML diagnoses who initiated first TKI treatment (imatinib, dasatinib, nilotinib, or bosutinib) in 2012 or later from United States administrative health claims databases (01/01/2007-06/30/2022). Treatment sequence and time to treatment discontinuation/switch were assessed. NOPT, identified based on treatment modification/adherence criteria, and its associated incremental healthcare resource utilization and medical costs were evaluated. Nearly a quarter of patients experienced NOPT, as indicated by early treatment modifications or low treatment adherence. NOPT was associated with significant incremental healthcare resource utilization (80% more inpatient admissions; twice as many inpatient days; 30% more outpatient visits) and medical costs (adjusted mean cost difference=$13,551 per-patient-per-year). Given the lack of information on reasons of treatment modification in health claims data, NOPT was identified based on indicators of management of intolerance and resistance to TKI. These findings highlight that unmet clinical needs and significant economic burden still persist in this population and that patients with CML may benefit from using therapeutic options with better efficacy and tolerability profiles as first treatment.
- 21 May 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 743-752
Open AccessNon-optimal treatment with first tyrosine kinase inhibitor and associated economic burden in chronic myeloid leukemia
Although adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKI) approved by the Food and Drug Administration have demonstrated effectiveness in treating chronic myeloid leukemia (CML), patients often experience intolerance or resistance, leading to non-optimal treatment (NOPT). This study assessed the treatment patterns, as well as NOPT and its associated economic burden, in newly diagnosed patients with CML receiving first TKI treatment. This retrospective study identified adult patients with ≥2 CML diagnoses who initiated first TKI treatment (imatinib, dasatinib, nilotinib, or bosutinib) in 2012 or later from United States administrative health claims databases (01/01/2007-06/30/2022). Treatment sequence and time to treatment discontinuation/switch were assessed. NOPT, identified based on treatment modification/adherence criteria, and its associated incremental healthcare resource utilization and medical costs were evaluated. Nearly a quarter of patients experienced NOPT, as indicated by early treatment modifications or low treatment adherence. NOPT was associated with significant incremental healthcare resource utilization (80% more inpatient admissions; twice as many inpatient days; 30% more outpatient visits) and medical costs (adjusted mean cost difference=$13,551 per-patient-per-year). Given the lack of information on reasons of treatment modification in health claims data, NOPT was identified based on indicators of management of intolerance and resistance to TKI. These findings highlight that unmet clinical needs and significant economic burden still persist in this population and that patients with CML may benefit from using therapeutic options with better efficacy and tolerability profiles as first treatment.
- Open Access
- 4 August 2023
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 7 (5) , 811-822
Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases
Background Crohn’s-related rectovaginal fistulas (RVF) greatly impact quality of life and are notoriously difficult to treat. The aim of this study was to assess the burden of recurrent episodes of care for RVF and its economic impact. Methods A retrospective observational cohort study of administrative US claims databases was conducted. Eligible patients were female adults, with a diagnosis code for Crohn’s disease with or without a diagnosis/procedural code for RVF. For the RVF cohort, rates of recurrence of RVF episodes of care were estimated using Kaplan–Meier analyses. Healthcare resource utilization (HCRU) and direct healthcare costs were compared between the RVF cohort and RVF-free cohort. Results Mean ages in the RVF cohort (n = 963) and RVF-free cohort (n = 56,564) were 47.2 and 50.8 years, with a mean follow-up period of 58.7 and 49.8 months, respectively. For the RVF cohort, the probability of having a second RVF episode of care within 2 years of the first one was estimated to be 35.9% and of having a third episode within 2 years of the second was 47.8%. During the first 2 years, the RVF cohort had 67% more inpatient admissions than the RVF-free cohort with each RVF episode of care being associated with 16% more admissions. The estimated incremental cost associated with having RVF was US$17,561, with an incremental cost of US$11,607 for each additional RVF episode of care. Conclusions This real-world study highlights the significant impact of RVF in patients with Crohn’s disease with regard to repeat interventions and associated HCRU and direct healthcare costs, suggesting novel therapeutics are needed in this patient population.
- 4 August 2023
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 7 (5) , 811-822
Open AccessDisease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases
Background Crohn’s-related rectovaginal fistulas (RVF) greatly impact quality of life and are notoriously difficult to treat. The aim of this study was to assess the burden of recurrent episodes of care for RVF and its economic impact. Methods A retrospective observational cohort study of administrative US claims databases was conducted. Eligible patients were female adults, with a diagnosis code for Crohn’s disease with or without a diagnosis/procedural code for RVF. For the RVF cohort, rates of recurrence of RVF episodes of care were estimated using Kaplan–Meier analyses. Healthcare resource utilization (HCRU) and direct healthcare costs were compared between the RVF cohort and RVF-free cohort. Results Mean ages in the RVF cohort (n = 963) and RVF-free cohort (n = 56,564) were 47.2 and 50.8 years, with a mean follow-up period of 58.7 and 49.8 months, respectively. For the RVF cohort, the probability of having a second RVF episode of care within 2 years of the first one was estimated to be 35.9% and of having a third episode within 2 years of the second was 47.8%. During the first 2 years, the RVF cohort had 67% more inpatient admissions than the RVF-free cohort with each RVF episode of care being associated with 16% more admissions. The estimated incremental cost associated with having RVF was US$17,561, with an incremental cost of US$11,607 for each additional RVF episode of care. Conclusions This real-world study highlights the significant impact of RVF in patients with Crohn’s disease with regard to repeat interventions and associated HCRU and direct healthcare costs, suggesting novel therapeutics are needed in this patient population.
- 26 March 2018
- Published by Springer Nature in Advances in Therapy
- Vol. 35 (4) , 482-493
Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Recent approval of novel agents has changed the treatment landscape for post menopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) metastatic breast cancer (mBC). The objective of this study was to describe contemporary treatment patterns among postmenopausal women with HR+/HER2− mBC in the real-world setting.
- 26 March 2018
- Published by Springer Nature in Advances in Therapy
- Vol. 35 (4) , 482-493
Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Recent approval of novel agents has changed the treatment landscape for post menopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) metastatic breast cancer (mBC). The objective of this study was to describe contemporary treatment patterns among postmenopausal women with HR+/HER2− mBC in the real-world setting.